Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy, safety, and tolerability of flexible doses of intranasal esketamine in combination with an oral antidepressant for treatm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• SPRAVATO (ESKETAMINE HYDROCHLORIDE)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Treatment-resistant Depression | Phase 3 | Status: COMPLETED | Results posted: 2019-04-19